AG真人官方

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- Pediatrix Medical Group, Inc. (NYSE: MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended December 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.51.

For the 2024 fourth quarter, Pediatrix reported the following results:

• Net revenue of $502 million;
• Net income of $30 million; and
• Adjusted EBITDA of $69 million.

鈥淥ur strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions,鈥� said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. 鈥淚 am honored and excited to reassume the role of Chief Executive Officer, and I am committed to furthering the Company鈥檚 strategic focus on supporting clinical excellence, strengthening our hospital and health system relationships, and optimizing our operating efficiency. We believe this focus, supported by our financial strength, will benefit all of our stakeholders.鈥�

Operating Results鈥� Three Months Ended December 31, 2024

Pediatrix鈥檚 net revenue for the three months ended December 31, 2024 was $502.4 million, compared to $496.4 million for the prior-year period. This increase reflected growth in same-unit revenue of 8.7 percent, partially offset by the impact of non-same unit activity, primarily practice dispositions.

Same-unit revenue from net reimbursement-related factors increased by 5.9 percent for the 2024 fourth quarter as compared to the prior-year period. This increase primarily reflects improved payor mix and modest improvements in hospital contract administrative fees. The percentage of services reimbursed by commercial and other non-government payors increased by approximately 200 basis points compared to the prior year period.

Same-unit revenue attributable to patient volume increased by 2.8 percent for the 2024 fourth quarter as compared to the prior-year period. Shown below are year-over-year percentage changes in certain same-unit volume statistics for the three months and year ended December 31, 2024. (Note: figures in the below table reflect contributions only to net patient service revenue and exclude other contributions to total same-unit revenue, including contract and administrative fees.)

For the 2024 fourth quarter, practice salaries and benefits expense was $349.0 million, compared to $363.6 million for the prior-year period. This comparison primarily reflects the impact of practice disposition activity, partially offset by increases in same-unit clinical compensation costs, including incentive compensation based on practice results.

For the 2024 fourth quarter, general and administrative expenses were $63.6 million, as compared to $53.1 million for the prior-year period. This comparison primarily reflects higher incentive compensation based on financial results.

For 2024 fourth quarter, transformational and restructuring related expenses totaled $23.6 million. These expenses related primarily to practice dispositions, revenue cycle management transition activities and position eliminations.

Adjusted EBITDA, which is defined as earnings before interest, taxes, depreciation and amortization, transformational and restructuring related expenses, adjustments to goodwill impairment and loss on disposal of businesses, was $68.7 million for the 2024 fourth quarter, compared to $50.8 million for the prior-year period.

Depreciation and amortization expense was $6.9 million for the fourth quarter of 2024, compared to $9.1 million for the prior-year period. This comparison was primarily related to a decrease in depreciation expense related to non-same unit activity, primarily practice dispositions.

Interest expense was $9.7 million for the fourth quarter of 2024, compared to $10.1 million for the fourth quarter of 2023.

Pediatrix generated net income of $30.5 million, or $0.36 per diluted share, for the 2024 fourth quarter, based on a weighted average 85.2 million shares outstanding. This compares with a net loss of $124.3 million, or $1.50 per diluted share, for the 2023 fourth quarter, based on a weighted average 82.7 million shares outstanding.

For the fourth quarter of 2024, Pediatrix reported Adjusted EPS of $0.51, compared to $0.32 for the fourth quarter of 2023. For these periods, Adjusted EPS is defined as diluted income per common and common equivalent share excluding non-cash amortization expense, stock-based compensation expense, transformational and restructuring related expenses, loss on disposal of businesses, tax effects and related adjustments to goodwill impairment and discrete tax events.

Operating Results 鈥� Year Ended December 31, 2024

For the year ended December 31, 2024, Pediatrix generated revenue of $2.01 billion, compared to $1.99 billion for the prior-year period. Pediatrix generated a net loss of $99.1 million, or $1.19 per share, for the year ended December 31, 2024, based on a weighted average 83.3 million shares outstanding, which compares to a net loss of $60.4 million, or $0.73 per share, based on a weighted average 82.2 million shares outstanding for prior year. Adjusted EBITDA for the year ended December 31, 2024 was $224.0 million, compared to $200.4 million for the prior year. For the year ended December 31, 2024, Pediatrix reported Adjusted EPS of $1.51, compared to $1.26 in the same period of 2023.

Financial Position and Cash Flow 鈥� Continuing Operations

Pediatrix had cash and cash equivalents of $229.9 million at December 31, 2024, compared to $73.3 million at December 31, 2023, and net accounts receivable at December 31, 2024 were $260.0 million.

For the fourth quarter of 2024, Pediatrix generated cash from continuing operations of $134.8 million, compared to $73.0 million during the fourth quarter of 2023. During the fourth quarter of 2024, the Company used $3.4 million to fund capital expenditures.

At December 31, 2024, Pediatrix had total debt outstanding of $616 million, consisting of its $400 million in 5.375% Senior Notes due 2030 and $216 million in borrowings under its Term A Loan. At December 31, 2024, the Company had no outstanding borrowings under its $450 million revolving line of credit.

Portfolio Management Update

As previously disclosed, during the second quarter of 2024, Pediatrix formalized its practice portfolio management plans, resulting in a decision to exit almost all of its affiliated office-based practices and its primary and urgent care service line.

The Company completed these plans on or prior to December 31, 2024. In aggregate, the office-based practices that the Company exited and the primary and urgent care clinics that have been divested contributed net revenue of approximately $200 million in 2023. As previously disclosed, Pediatrix expects that the annualized favorable impact to Adjusted EBITDA resulting from its portfolio management plans to be approximately $30 million, based on 2023 financial information. A portion of this expected favorable impact was realized during 2024.

Preliminary 2025 Outlook

On a preliminary basis, Pediatrix anticipates that its 2025 Adjusted EBITDA, as defined above, will be in a range of $215 million to $235 million.

Non-GAAP Measures

A reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable GAAP measures for the three months and year ended December 31, 2024 and 2023 is provided in the financial tables of this press release.

Earnings Conference Call

Pediatrix will host an investor conference call to discuss the quarterly results at 9 a.m., ET today. The conference call Webcast may be accessed from the Company鈥檚 Website, . A replay of the conference call will also be available at .

ABOUT PEDIATRIX MEDICAL GROUP

Pediatrix庐 Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology complemented by multiple pediatric subspecialties. The group鈥檚 high-quality, evidence-based care is bolstered by significant investments in research, education, quality-improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,400 affiliated physicians and other clinicians. To learn more about Pediatrix, visit or follow us on , , and the . Investment information can be found at .

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the 鈥淪ecurities Act鈥�), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company鈥檚 objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as 鈥渂elieve,鈥� 鈥渉ope,鈥� 鈥渕ay,鈥� 鈥渁nticipate,鈥� 鈥渟hould,鈥� 鈥渋ntend,鈥� 鈥減lan,鈥� 鈥渨ill,鈥� 鈥渆xpect,鈥� 鈥渆stimate,鈥� 鈥減roject,鈥� 鈥減ositioned,鈥� 鈥渟trategy鈥� and similar expressions, and are based on assumptions and assessments made by the Company鈥檚 management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company鈥檚 most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled 鈥淩isk Factors鈥�, as well the Company鈥檚 current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the Company鈥檚 practice portfolio management plans and whether the Company is able to achieve the expected favorable impact to Adjusted EBITDA therefrom; the impact of the Company鈥檚 termination of its then third-party revenue cycle management provider and transition to a hybrid revenue cycle management model with one or more new third-party service providers, including any transition costs associated therewith; the impact of surprise billing legislation; the effects of economic conditions on the Company鈥檚 business; the effects of the Affordable Care Act and potential healthcare reform; the Company鈥檚 relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the Company鈥檚 ability to comply with the terms of its debt financing arrangements; the impact of management transitions; the timing and contribution of future acquisitions or organic growth initiatives; the effects of share repurchases; and the effects of the Company鈥檚 transformation initiatives, including its reorientation on, and growth strategy for, its hospital based and maternal fetal businesses.

听

View source version on businesswire.com:

Charles Lynch

Senior Vice President, Finance and Strategy

954-384-0175, x 5692

[email protected]

Source: Pediatrix Medical Group, Inc.